Report
Biomarker-based tests for the decision for or against adjuvant systemic chemotherapy in primary breast cancer - Addendum to Commission D14-01
Report documents
-
Executive summary of the Addendum to Commission D14-01
Biomarker-based tests for the decision for or against adjuvant systemic chemotherapy in primary breast cancer - Addendum to Commission D14-01
-
Addendum
Biomarker-based tests for the decision for or against adjuvant systemic chemotherapy in primary breast cancer - Addendum to Commission D14-01
Press releases
Biomarker tests in breast cancer: New study data indicate advantage for certain patients
TAILORx: first study with sufficient observation period for the benefit assessment
Additional information
IQWiG health information
After surgery for early-stage breast cancer, chemotherapy can reduce the risk of the cancer returning. But sometimes the disadvantages may outweigh the advantages.
Project details
- Project no.
- D18-01
- Commission
- Commission awarded on 06.07.2018 by the Federal Joint Committee (GBA).
- Report type
- Report
- Status
- Commission completed
- Department/Division
- Non-Drug Interventions
- Topic
- Diagnostics, Cancer
Connected Projects
-
Report
Biomarker-based tests for the decision for or against adjuvant systemic chemotherapy in primary breast cancer
Status: Commission completed